Stock of the Day

Allergan (AGN)

$193.02

$0.00 (0.0%)

Market Cap: $63.50B

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International.

It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Allergan Bull Case

Here are some ways that investors could benefit from investing in Allergan plc:

• The current stock price is around $720, reflecting strong market confidence in Allergan plc's growth potential.
• Allergan plc has a diverse portfolio of products across various therapeutic areas, including innovative treatments for neurodegenerative disorders and advanced medical aesthetics, which can drive revenue growth.
• The company is actively developing novel therapies, such as RST-001, a gene therapy for retinitis pigmentosa, positioning itself at the forefront of cutting-edge medical advancements.
• Strategic collaborations with companies like Editas Medicine, Inc. enhance Allergan plc's research capabilities and expand its product pipeline, potentially leading to lucrative market opportunities.
• Allergan plc's established presence in both the US and international markets allows for a broad customer base, reducing dependency on any single market and mitigating risks.

Allergan Bear Case

Investors should be bearish about investing in Allergan plc for these reasons:

• Increased competition in the pharmaceutical industry, particularly in the areas of medical aesthetics and autoimmune treatments, could pressure Allergan plc's market share and pricing strategies.
• Regulatory challenges and the lengthy approval process for new drugs can delay product launches, impacting potential revenue streams.
• Allergan plc's reliance on a few key products for a significant portion of its revenue may pose risks if those products face market challenges or patent expirations.
• Market volatility and economic uncertainties can affect investor sentiment and stock performance, which may lead to fluctuations in Allergan plc's stock price.
• Potential legal issues related to product liability or patent disputes could result in financial liabilities and damage the company's reputation.